Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BCRX
stocks logo

BCRX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
151.06M
+14.85%
0.041
-159.23%
156.33M
+7.42%
0.036
-127.47%
Estimates Revision
The market is revising Downward the revenue expectations for BioCryst Pharmaceuticals, Inc. (BCRX) for FY2025, with the revenue forecasts being adjusted by -0.8% over the past three months. During the same period, the stock price has changed by -5.32%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.8%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-42.24%
In Past 3 Month
Stock Price
Go Down
down Image
-5.32%
In Past 3 Month
Wall Street analysts forecast BCRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCRX is 19.27 USD with a low forecast of 8.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast BCRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCRX is 19.27 USD with a low forecast of 8.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
2 Hold
0 Sell
Strong Buy
Current: 7.830
sliders
Low
8.00
Averages
19.27
High
30.00
Current: 7.830
sliders
Low
8.00
Averages
19.27
High
30.00
Citizens JMP
Jonathan Wolleben
Outperform
downgrade
$27 -> $25
2025-11-05
Reason
Citizens JMP
Jonathan Wolleben
Price Target
$27 -> $25
2025-11-05
downgrade
Outperform
Reason
Citizens JMP analyst Jonathan Wolleben lowered the firm's price target on BioCryst to $25 from $27 and keeps an Outperform rating on the shares following the Q3 earnings report. The firm likes the continued positive trajectory of Orladeyo sales fueled by a growing prescriber base, consistent high patient retention, and strong reimbursement dynamics, the analyst tells investors in a research note. BioCryst is well-positioned for growth, with Orladeyo sales continuing to move higher, pipeline expansion with the strategic addition of navenibart, and potentially de-risking Netherton syndrome data on the horizon, the firm states.
Barclays
Equal Weight
downgrade
$11 -> $9
2025-11-04
Reason
Barclays
Price Target
$11 -> $9
2025-11-04
downgrade
Equal Weight
Reason
Barclays lowered the firm's price target on BioCryst to $9 from $11 and keeps an Equal Weight rating on the shares. The company reported an inline Q3 for Orladeyo with narrowed guidance, the analyst tells investors in a research note.
Cantor Fitzgerald
Steve Seedhouse
Overweight
maintain
$24 -> $26
2025-10-15
Reason
Cantor Fitzgerald
Steve Seedhouse
Price Target
$24 -> $26
2025-10-15
maintain
Overweight
Reason
Cantor Fitzgerald analyst Steve Seedhouse raised the firm's price target on BioCryst (BCRX) to $26 from $24 and keeps an Overweight rating on the shares. BioCryst is buying top pick Astria Therapeutics (ATXS) for $700M in enterprise value, and the deal is a "terrific" value for BioCryst, even before accounting for essentially total SG&A synergy, and it allows BioCryst to protect and extend its core HAE commercial leadership position through navenibart's loss of exclusivity in 2042, the analyst tells investors in a research note.
Jefferies
Buy
to
Hold
downgrade
$30 -> $13
2025-10-14
Reason
Jefferies
Price Target
$30 -> $13
2025-10-14
downgrade
Buy
to
Hold
Reason
Jefferies downgraded Astria Therapeutics to Hold from Buy with a price target of $13, down from $30, after the company reached an agreement to be acquired by BioCryst (BCRX) for cash and stock at an implied value of $13 per share, or $700M. The firm expects the deal to close on time in Q1 of 2026.
Jefferies
Maury Raycroft
Buy
maintain
$14 -> $15
2025-10-14
Reason
Jefferies
Maury Raycroft
Price Target
$14 -> $15
2025-10-14
maintain
Buy
Reason
Jefferies analyst Maury Raycroft raised the firm's price target on BioCryst (BCRX) to $15 from $14 and keeps a Buy rating on the shares following the announcement that the company will acquire Astria Therapeutics (ATXS) for $13 per share. The firm said the multiple reflects a discount likely due to crowded hereditary angioedema landscape, potential clinical/regulatory risks and FTC clearance risk. Jefferies added that Astria stockholders will own approximately 15% of pro forma equity in the combined company, which likely lowers the chance of another bidder.
Evercore ISI
Outperform
to
In Line
downgrade
$12 -> $8
2025-10-01
Reason
Evercore ISI
Price Target
$12 -> $8
2025-10-01
downgrade
Outperform
to
In Line
Reason
Evercore ISI downgraded BioCryst to In Line from Outperform with a price target of $8, down from $12. Though Orladeyo "should have some nice longevity," the firm doesn't see the product as "a winner in the HAE space," the analyst tells investors.
See All Ratings

Valuation Metrics

The current forward P/E ratio for BioCryst Pharmaceuticals Inc (BCRX.O) is 28.40, compared to its 5-year average forward P/E of -32.64. For a more detailed relative valuation and DCF analysis to assess BioCryst Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-32.64
Current PE
28.40
Overvalued PE
69.45
Undervalued PE
-134.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-8.22
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
54.22
Undervalued EV/EBITDA
-70.65

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
6.84
Current PS
0.00
Overvalued PS
12.59
Undervalued PS
1.10
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 1599.59% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 1599.59% over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

BCRX News & Events

Events Timeline

(ET)
2025-12-04
07:10:00
BioCryst Grants Stock Options for 57,100 Shares to New Employees
select
2025-12-03 (ET)
2025-12-03
07:10:00
BioCryst Receives Early Termination for Acquisition of Astria
select
2025-11-06 (ET)
2025-11-06
08:28:24
BioCryst Reveals New ORLADEYO Data at ACAAI Conference
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-03Newsfilter
PinnedBioCryst Receives Early Termination for Astria Acquisition Under HSR Act
  • Antitrust Progress: BioCryst Pharmaceuticals announced that its acquisition of Astria Therapeutics has received early termination under the HSR Act, satisfying one of the merger conditions, with expectations to close in Q1 2026, thereby enhancing its market position in rare diseases.
  • Merger Expectations: This merger will allow BioCryst to integrate Astria's product line, further enriching its portfolio of rare disease medications, which is anticipated to boost overall revenue and market competitiveness.
  • Financial Impact: BioCryst expects to incur significant debt during the merger process, which may affect cash flow management; however, successful integration is projected to yield synergies that enhance long-term profitability.
  • Shareholder Attention: The merger requires approval from Astria's shareholders, and BioCryst must ensure all other closing conditions are met to avoid potential legal risks and management distractions, ensuring a smooth merger process.
[object Object]
Preview
8.5
12-03Globenewswire
BioCryst Receives HSR Act Termination for Astria Acquisition
  • Antitrust Review Completed: BioCryst Pharmaceuticals announced the early termination of the antitrust review for its acquisition of Astria Therapeutics, satisfying a key condition for the merger, which is expected to close in Q1 2026, thereby accelerating the company's market expansion in rare diseases.
  • Strategic Significance of Merger: This merger will enable BioCryst to integrate Astria's R&D resources, advancing its product line in treating hereditary angioedema and other rare diseases, further solidifying its market position and enhancing competitiveness.
  • Financial Impact Expectations: BioCryst anticipates incurring significant debt during the merger process, which may affect cash flow management; however, successful integration is expected to yield synergies that enhance overall profitability.
  • Investor Attention: BioCryst has filed a registration statement with the SEC regarding the merger, urging investors to carefully read the relevant documents to obtain critical information about the merger and ensure effective participation in shareholder voting post-completion.
[object Object]
Preview
9.0
11-30Yahoo Finance
BioCryst Data Reveals Significant Psychosocial Impact of HAE on Children and Their Caregivers

  • BioCryst Pharmaceuticals Overview: BioCryst Pharmaceuticals (NASDAQ: BCRX) is highlighted as a promising investment, particularly following the announcement of new data on the psychosocial impact of hereditary angioedema (HAE) on pediatric patients and their caregivers.

  • APeX-P Clinical Trial Results: The ongoing APeX-P clinical trial revealed a significant reduction in monthly HAE attack rates in children aged 2 to under 12 years treated with ORLADEYO (berotralstat), showcasing its safety and effectiveness over a mean treatment exposure of 63.9 weeks.

  • ORLADEYO Approval and Usage: ORLADEYO, previously approved by the FDA for HAE prophylaxis in patients aged 12 and older, is not recommended for acute HAE attacks, and caution is advised for dosages exceeding 150 mg due to potential side effects.

  • Investment Considerations: While BCRX shows potential, the article suggests that certain AI stocks may offer better upside potential and lower risk, encouraging readers to explore other investment opportunities.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is BioCryst Pharmaceuticals Inc (BCRX) stock price today?

The current price of BCRX is 7.83 USD — it has decreased -0.25 % in the last trading day.

arrow icon

What is BioCryst Pharmaceuticals Inc (BCRX)'s business?

BioCryst Pharmaceuticals, Inc. is a biotechnology company focused on improving the lives of people living with hereditary angioedema and other rare diseases. The Company leverages its expertise in designing to develop first-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. Its marketed products include oral, once-daily ORLADEYO for the prevention of hereditary angioedema (HAE) attacks and RAPIVAB (peramivir injection) for the treatment of acute uncomplicated influenza in the United States. Its other products and product candidates include BCX10013, RAPIACTA (peramivir injection), PERAMIFLU (peramivir injection), and early-stage discovery programs. BCX10013, is a potent and specific Factor D inhibitor. RAPIACTA focuses on uncomplicated seasonal influenza. The RAPIVAB (peramivir injection) is approved in the United States for the treatment of acute uncomplicated influenza for patients six months and older.

arrow icon

What is the price predicton of BCRX Stock?

Wall Street analysts forecast BCRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BCRX is 19.27 USD with a low forecast of 8.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is BioCryst Pharmaceuticals Inc (BCRX)'s revenue for the last quarter?

BioCryst Pharmaceuticals Inc revenue for the last quarter amounts to 159.40M USD, increased 36.14 % YoY.

arrow icon

What is BioCryst Pharmaceuticals Inc (BCRX)'s earnings per share (EPS) for the last quarter?

BioCryst Pharmaceuticals Inc. EPS for the last quarter amounts to 0.06 USD, decreased -185.71 % YoY.

arrow icon

What changes have occurred in the market's expectations for BioCryst Pharmaceuticals Inc (BCRX)'s fundamentals?

The market is revising Downward the revenue expectations for BioCryst Pharmaceuticals, Inc. (BCRX) for FY2025, with the revenue forecasts being adjusted by -0.8% over the past three months. During the same period, the stock price has changed by -5.32%.
arrow icon

How many employees does BioCryst Pharmaceuticals Inc (BCRX). have?

BioCryst Pharmaceuticals Inc (BCRX) has 580 emplpoyees as of December 05 2025.

arrow icon

What is BioCryst Pharmaceuticals Inc (BCRX) market cap?

Today BCRX has the market capitalization of 1.65B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free